摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-methyl 3-(4-hydroxyphenyl)-2-methoxypropanoate | 267228-43-3

中文名称
——
中文别名
——
英文名称
(S)-methyl 3-(4-hydroxyphenyl)-2-methoxypropanoate
英文别名
S(-)-methyl 2-methoxy-3-(4-hydroxyphenyl)propionate;methyl (2S)-3-(4-hydroxyphenyl)-2-methoxypropanoate
(S)-methyl 3-(4-hydroxyphenyl)-2-methoxypropanoate化学式
CAS
267228-43-3
化学式
C11H14O4
mdl
——
分子量
210.23
InChiKey
DRDPVLHCRHQIKR-JTQLQIEISA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    15
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    55.8
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (S)-methyl 3-(4-hydroxyphenyl)-2-methoxypropanoate2-氯-N-[2-(4-乙氧基苯基)乙基]乙酰胺四丁基碘化铵potassium carbonate 、 potassium iodide 作用下, 以 乙腈 为溶剂, 反应 24.0h, 以89.9%的产率得到(S)-methyl 2-ethoxy-3-(4-(2-(4-ethoxyphenylethylamino)-2-oxoethoxy)phenyl)propanoate
    参考文献:
    名称:
    Syntheses of a Selective Peroxisome Proliferator Activated Receptor Modulator and Practical New Preparations of 2-(4-Alkoxyphenyl)ethylamines
    摘要:
    This article describes chemistry that was developed to give access to multigram quantities of the selective peroxisome proliferator activated receptor modulator (SPPARM), compound 1.(1) Fischer esterifications, phase transfer-catalyzed alkylations, amide couplings, crystallizations, and a new synthesis were developed to accomplish this task. In addition, an efficient method for preparing 2-(4-alkoxyphenyl)ethylamines 7a-d from tyramine 9 was developed that involves O-alkylation of intermediate Schiff base 11 and subsequent acid-catalyzed hydrolysis to afford the target molecules as crystalline hydrochloride salts.
    DOI:
    10.1021/op800215a
  • 作为产物:
    参考文献:
    名称:
    An Asymmetric Synthesis of PPAR-? Agonist Navaglitazar from (+)-Methyl (2S,3R)-3-(4-methoxyphenyl)glycidate
    摘要:
    这段文字的中文翻译如下:

    描述了一种从商业上可获得的(+)-甲基(2S,3R)-3-(4-甲氧基苯基)环氧乙酸酯合成纳瓦格利塞的不对称合成方法,纳瓦格利塞是一种过氧化物酶体增殖物激活受体(PPAR)α激动剂。这种新合成方法具有高总收率、低溶剂使用量、结晶中间体和操作简便的特点。

    DOI:
    10.2533/chimia.2006.580
点击查看最新优质反应信息

文献信息

  • Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine
    申请人:——
    公开号:US20030236254A1
    公开(公告)日:2003-12-25
    Novel &bgr;-aryl-&agr;-substituted propanoic acids having hypolipidemic and hypocholesteremic activities.
    具有降脂和降胆固醇活性的新型β-芳基-α-取代丙酸。
  • Novel heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
    申请人:CADILA HEALTHCARE LIMITED
    公开号:US20030199498A1
    公开(公告)日:2003-10-23
    The present invention relates to novel substituted pyrrole compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel substituted pyrrole compounds of the general formula (I), their analogs, their derivatives, their polymorphs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them. 1 This invention also relates to the process for preparing such compounds, a composition containing such a compound and the use of such a compound and composition in medicine.
    本发明涉及新型取代吡咯化合物,其衍生物,类似物,互变异构体,立体异构体,多型体,药学上可接受的盐,药学上可接受的溶剂合物以及含有它们的药学上可接受的组合物。本发明特别涉及一般式(I)的新型取代吡咯化合物,其类似物,衍生物,多型体,互变异构体,药学上可接受的盐,药学上可接受的溶剂合物以及含有它们的药物组合物。本发明还涉及制备这类化合物的方法,含有这类化合物的组合物以及这类化合物和组合物在医学中的用途。
  • NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN MEDICINE
    申请人:LOHRAY Braj Bhushan
    公开号:US20080188402A1
    公开(公告)日:2008-08-07
    The present invention relates to novel substituted pyrrole compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel substituted pyrrole compounds of the general formula (I), their analogs, their derivatives, their polymorphs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them. This invention also relates to the process for preparing such compounds, a composition containing such a compound and the use of such a compound and composition in medicine.
    本发明涉及新的取代吡咯化合物、它们的衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和含有它们的药学上可接受的组成物。本发明特别涉及一般式(I)的新的取代吡咯化合物、它们的类似物、衍生物、多晶形态、互变异构体、药学上可接受的盐、药学上可接受的溶剂和含有它们的药物组成物。本发明还涉及制备这种化合物的过程、含有这种化合物的组成物以及这种化合物和组成物在医学上的使用。
  • Novel Pyrroles Having Hypolipidemic Hypocholesteremic Activities, Process for Their Preparation and Pharmaceutical Compositions Containing Them and Their Use in Medicine
    申请人:Lohray Bhushan Braj
    公开号:US20070238776A1
    公开(公告)日:2007-10-11
    The present invention relates to novel substituted pyrrole compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel substituted pyrrole compounds of the general formula (I), their analogs, their derivatives, their polymorphs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them. The invention also relates to the process for preparing such compounds, a composition containing such a compound and the use of such a compound and composition in medicine. The compounds lower triglyceride levels in blood and may be useful in the treatment of obesity, hyperlipidaemia, hypercholesteremia, syndrome X and diabetes.
    本发明涉及新型取代吡咯化合物,其衍生物,类似物,互变异构体,立体异构体,多晶形态,其药学上可接受的盐,其药学上可接受的溶剂和含有它们的药学上可接受的组合物。本发明特别涉及一般式(I)的新型取代吡咯化合物,其类似物,衍生物,多晶形态,互变异构体,药学上可接受的盐,药学上可接受的溶剂和含有它们的药物组合物。本发明还涉及制备这种化合物的过程,含有这种化合物的组合物以及在医学中使用这种化合物和组合物。这些化合物可以降低血液中的三酰甘油水平,并可能在肥胖症,高脂血症,高胆固醇血症,X综合症和糖尿病的治疗中有用。
  • Modulators of peroxisome proliferator activated receptors
    申请人:Brooks Alisa Dawn
    公开号:US20070276138A1
    公开(公告)日:2007-11-29
    Disclosed is a compound represented by Structural Formula (I): Ar is a substituted or unsubstituted aromatic group. Q is a covalent bond, —CH 2 — or —CH 2 CH 2 —; W is a substituted or unsubstituted alkylene or a substituted or unsubstituted heteroalkylene linking group from two to ten atoms in length, preferably from two to seven atoms in length. Phenyl Ring A is optionally substituted with up to four substituents in addition to R 1 and W. R 1 is —(CH 2 ) n —CH(OR 2 )—(CH 2 ) m E, —(CH)═C(OR 2 )—(CH 2 ) m E, —(CH 2 ) n —CH(Y)—(CH 2 ) m E or —(CH)═C(Y)—(CH 2 ) m E; wherein E is COOR 3 , C 1 -C 3 -alkylnitrile, carboxamide, sulfonamide, acylsulfonamide or tetrazole and wherein sulfonamide, acylsulfonamide and tetrazole are optionally substituted with one or more substituents independently selected from: C 1 -C 6 alkyl, haloalkyl and aryl-C 0-4 -alkyl; R 2 is —H, an aliphatic group, a substituted aliphatic group, haloalkyl, an aromatic group, a substituted aromatic group, —COR 4 , —COOR 4 , —CONR 5 R 6 , —C(S)R 4 , —C(S)OR 4 or —C(S)NR 5 R 6 . R 3 is —H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. Y is —O—, —CH 2 —, —CH 2 CH 2 — or —CH═CH— and is bonded to a carbon atom in Phenyl Ring A that is ortho to R 1 . R 4 -R 6 are independently —H, an aliphatic group, a substituted aliphatic group, an aromatic group or a substituted aromatic group. n and m are independently 0, 1 or 2.
    公开了一种化合物,其结构式表示为(I):其中Ar是取代或未取代的芳香族基团。Q是共价键,-CH2-或-CH2CH2-;W是取代或未取代的烷基或取代或未取代的异烷基连接基团,长度为两到十个原子,优选长度为两到七个原子。苯环A可以选择性地用最多四个取代基取代R1和W。R1是-(CH2)n-CH(OR2)-(CH2)mE,-(CH)=C(OR2)-(CH2)mE,-(CH2)n-CH(Y)-(CH2)mE或-(CH)=C(Y)-(CH2)mE;其中E是COOR3,C1-C3-烷基腈,羧酰胺,磺酰胺,酰基磺酰胺或四唑,其中磺酰胺,酰基磺酰胺和四唑可以选择性地用一个或多个取代基取代,独立地选自C1-C6烷基,卤代烷基和芳基-C0-4-烷基;R2是-H,一种脂肪基,一种取代的脂肪基,卤代烷基,一种芳香基,一种取代的芳香基,-COR4,-COOR4,-CONR5R6,-C(S)R4,-C(S)OR4或-C(S)NR5R6;R3是-H,一种脂肪基,一种取代的脂肪基,一种芳香基或一种取代的芳香基;Y是-O-,-CH2-,-CH2CH2-或-CH═CH-,并与苯环A中与R1正交的碳原子键合;R4-R6独立地是-H,一种脂肪基,一种取代的脂肪基,一种芳香基或一种取代的芳香基;n和m独立地为0、1或2。
查看更多